2022
Community-based referral for tuberculosis preventive therapy is effective for treatment completion
Shenoi S, Kyriakides T, Dokubo E, Guddera V, Vranken P, Desai M, Friedland G, Moll A. Community-based referral for tuberculosis preventive therapy is effective for treatment completion. PLOS Global Public Health 2022, 2: e0001269. PMID: 36962910, PMCID: PMC10021376, DOI: 10.1371/journal.pgph.0001269.Peer-Reviewed Original ResearchTreatment completionCommunity-based identificationPreventive therapyIndependent predictorsGovernment primary care clinicsMedian age 35 yearsCommunity-based referralsHigher treatment completionMedian CD4 countTB preventive therapyTB endemic regionsTuberculosis preventive therapyComparison groupPrimary care clinicsClinic-based careAge 35 yearsCBR groupTeam of nursesSix-month courseMedian CD4Oral isoniazidCD4 countHIV careNight sweatsCare clinics
2015
Integrating Community-Based Interventions to Reverse the Convergent TB/HIV Epidemics in Rural South Africa
Gilbert JA, Long EF, Brooks RP, Friedland GH, Moll AP, Townsend JP, Galvani AP, Shenoi SV. Integrating Community-Based Interventions to Reverse the Convergent TB/HIV Epidemics in Rural South Africa. PLOS ONE 2015, 10: e0126267. PMID: 25938501, PMCID: PMC4418809, DOI: 10.1371/journal.pone.0126267.Peer-Reviewed Original ResearchConceptsTB/HIVHIV control strategiesMDR-TBXDR-TBHIV deathsHIV casesHIV epidemicRural South AfricaTB/HIV casesTB treatment delayIsoniazid preventive therapyDrug-resistant TBHIV treatment programsTreatment cure ratesHIV case findingHIV control effortsNovel screening programPreventive therapyTB casesTB treatmentTreatment delayHIV transmissionCure rateQuestionnaire's sensitivityScreening program
2010
Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis
Friedland G. Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 55: s37-s42. PMID: 21045598, PMCID: PMC4505738, DOI: 10.1097/qai.0b013e3181f9c0b6.Peer-Reviewed Original ResearchConceptsHepatitis CDrug interactionsDrug usersDrug useActive screening programsSpecial clinical challengeIsoniazid preventive therapySubstance abusersInjection drug usePharmacodynamic drug interactionsDrug-resistant organismsTreatment of tuberculosisInfectious disease comorbiditiesHIV/AIDSPreventive therapyTreatment initiationComorbid conditionsMedication adherenceHIV pandemicScreening programClinical challengeClinician expertiseTherapeutic successClinical consequencesInfection control